Thursday, November 02, 2017 -- In patients with medically treated angina and severe coronary stenosis, PCI did not increase exercise time by more than the effect of a placebo procedure. The efficacy of invasive procedures can be assessed with a placebo control, as is standard for pharmacotherapy.
Wednesday, November 29, 2017 -- (Natural News) You’ve probably heard of the placebo effect: Someone reports feeling better after taking a pill that is said to help some condition or other, only to later discover the pill did not contain any active ingredients at all. The person’s physical health didn’t change; feeling better was all in their mind. It’s always... Read More
Friday, November 03, 2017 -- Using a stent to reopen a blocked artery in or around the heart can be lifesaving for those having heart attacks. They’re also commonly used in those who have chest pain known as angina. But new research suggests stents may be more placebo than panacea for some patients.
Monday, November 06, 2017 -- A new study conducted by researchers at the Imperial College London suggests that the placebo effect experienced by patients who receive coronary artery stents might be larger than expected, even though stents themselves are life-saving.
Friday, November 24, 2017 -- In the first-ever, double-blinded, placebo-controlled trial, researchers tested the efficacy of heart stents in patients with stable angina. Angina is pain or discomfort in the chest due to a lack of oxygen in the blood flowing to the heart. This pain is not limited to the chest but can spread to the back, neck, arms, […] The post Are Heart Stents Effective in Patients With Stable Angina? appeared first on Medical News Bulletin | Health News and Medical Research.
Thursday, May 18, 2017 -- (MedPage Today) -- EuroCTO result, driven by less angina, challenges DECISION-CTO
Tuesday, August 22, 2017 -- Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients with evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucose-lowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a larger number of components, while more recent CVOTs almost exclusively use a composite
Friday, September 01, 2017 -- Background: An elevated circulating cystathionine concentration, which arises in part from insufficiencies of vitamin B-6, B-12, or folate, has been shown to be associated with cardiovascular disease (CVD) risk. Hydrogen sulfide (H2S) is a gasotransmitter involved in vasodilation, neuromodulation, and inflammation. Most endogenously produced H2S is formed by pyridoxal phosphate (PLP)-dependent enzymes by noncanonical reactions of the transsulfuration pathway that yield H2S concurrently form lanthionine and homolanthionine. Thus, plasma lanthionine and homolanthionine concentrations can provide relative information about H2S production in vivo. Objective: To determine the metabolic consequences of an elevated plasma cystathionine concentration in adults with stable angina pectoris (SAP), we conducted both targeted and untargeted metabolomic analyses. Methods: We conducted NMR and LC-mass spectrometry (MS) metabolomic analyses
Friday, November 03, 2017 -- ORBITA was a double-blind, randomized controlled trial that evaluated PCI vs. a placebo procedure for improved exercise capacity in patients with severe coronary disease who were receiving optimum medical therapy.
Wednesday, June 28, 2017 -- A new study has shown that every 1 year increase in reproductive duration-years from menarche to menopause-was associated with a 3% reduction in a woman's risk of angina or stroke.
Monday, June 05, 2017 -- AbstractBackground Left main coronary artery (LMCA) compression is increasingly recognized as a cause of angina in pulmonary arterial hypertension (PAH). Objectives This study aimed to evaluate the prevalence of LMCA extrinsic compression from a dilated pulmonary artery (PA) in patients with PAH and angina or angina-like symptoms, determine the usefulness of screening with computed tomography coronary angiography (CTCA), and assess the safety and efficacy of percutaneous coronary interventions (PCIs). Methods All patients with PAH and angina or angina-like symptoms attending the center between May 1, 2008, and December 31, 2013, underwent CTCA. Patients with confirmed LMCA stenosis on selective coronary angiography had PCI. Results Of 765 patients with PAH, 121 had angina or angina-like symptoms. Ninety-four patients had abnormal
Monday, October 30, 2017 -- AbstractBackground Coronary vasomotor dysfunction is an important mechanism for angina in patients with unobstructed coronary arteries. Objectives The purpose of this study was to determine sex differences in the prevalence and clinical presentation of vasomotor dysfunction in a European population and to examine sex differences in the dose of acetylcholine leading to a positive acetylcholine provocation test (ACH test). Methods Between 2007 and 2014, we included 1,379 consecutive patients with stable angina, unobstructed coronaries and ACH test performed for epicardial vasospasm or coronary microvascular dysfunction (CMD) due to microvascular spasm. The predictive value of sex, risk factors, symptoms, and noninvasive test results was analyzed by means of logistic regression. Results The mean patient age was 62 years, and 42%
Monday, January 22, 2018 -- AbstractBackground Recent studies suggested that perivascular components, such as perivascular adipose tissue (PVAT) and adventitial vasa vasorum (VV), play an important role as a source of various inflammatory mediators in cardiovascular disease. Objectives The authors tested their hypothesis that coronary artery spasm is associated with perivascular inflammation in patients with vasospastic angina (VSA) using 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Methods This study prospectively examined 27 consecutive VSA patients with acetylcholine-induced diffuse spasm in the left anterior descending artery (LAD) and 13 subjects with suspected angina but without organic coronary lesions or coronary spasm. Using CT coronary angiography and electrocardiogram-gated 18F-FDG PET/CT, coronary PVAT volume and coronary perivascular FDG uptake in the LAD were examined. In addition, adventitial VV formation in the LAD was
Thursday, November 02, 2017 -- Interventional cardiology began in Switzerland in 1977, when Andreas Gruentzig performed the first successful percutaneous transluminal coronary angioplasty (PTCA) on a 38-year-old man with angina and a focal proximal stenosis of the left anterior descending coronary artery. Despite numerous subsequent randomised trials and meta-analyses of these trials, which have shown no reduction in death or myocardial infarction,1 the use of percutaneous coronary intervention (PCI) has grown exponentially. Some of this growth was driven by data from clinical trials suggesting that PCI was more effective in relieving angina than medical therapy alone.
Thursday, November 02, 2017 -- Researchers at Imperial College London have explored the placebo effects of a coronary angioplasty procedure with stents for the first time.
Monday, November 06, 2017 -- No better than placebo procedure for stable angina patients with severe stenosis
Friday, August 04, 2017 -- Testing strategies are rapidly evolving to determine which patients with chest pain have CAD, and which of those have high enough risk to warrant revascularization. Driving reexamination of historical approaches to evaluate such patients are advances in coronary CT angiography technology, including new capabilities to determine coronary fractional flow reserve from CT images (FFR-CT). Cardiology Today spoke with Markus D. Scherer, MD, FACC, FSCCT, director of cardiac CT and structural heart imaging at Carolinas HealthCare System’s Sanger Heart & Vascular Institute in Charlotte, North Carolina, about how these developments are leading to changes in chest pain evaluation protocols, in efforts to improve patient outcomes while reducing overall health care costs.
Thursday, November 02, 2017 -- (MedPage Today) -- No symptom relief beyond placebo effect in first sham-controlled trial